Mode
Text Size
Log in / Sign up
N/A N=137 Randomized Quadruple-blind Treatment

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

Smoking Cessation · Nicotine Dependence

Enrolled (actual)
137
Serious AEs
9.5%
Results posted
May 2018
Primary outcome: Primary: 7-day Point-prevalence Smoking Abstinence — 2; 10 participants — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nicotine Replacement Treatment (NRT) (Drug); varenicline (Drug); Behavioral counseling for smoking cessation (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Brown University
Primary completion
Mar 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
7-day Point-prevalence Smoking Abstinence
2; 7 .30
PRIMARY
7-day Point-prevalence Smoking Abstinence
2; 7 .30
SECONDARY
Length of Longest Continuous Abstinence
6.25; 7.84 .50
SECONDARY
Percent Smoking Days
84.52; 77.12 .36
SECONDARY
Percent Smoking Days
84.52; 77.12 .36
SECONDARY
Percent Relapsed to Drug Use
8; 18 .31
SECONDARY
Percent Relapsed to Drug Use
8; 18 .31
SECONDARY
Percent Relapsed to Any Heavy Drinking
9; 8 .18
SECONDARY
Percent Relapsed to Any Heavy Drinking
9; 8 .18
SECONDARY
Beck Depression Inventory
5.19; 5.75 .75

Summary

The purpose of this study is to evaluate the effects of 12 weeks of varenicline as compared to nicotine replacement therapy for smoking cessation among outpatients in treatment for substance use disorders. The intervention also incorporates counseling (Brief Advice), (adapted for sobriety settings), skills training and medication management.

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of substance abuse or dependence by DSM-IV criteria
  • Currently smoking at least 10 cigarettes per day for the past 6 months

Exclusion Criteria

  • Active psychosis or marked organic impairment according to medical records, or evidence of hallucinations or delusions
  • Current use of any nicotine replacement, or other smoking cessation treatment
  • Medical contraindications for NRT (including pregnancy, nursing, women not using birth control during heterosexual sex, history of unstable angina, history of severe congestive heart failure, uncontrolled hypertension, lung cancer, supplemental oxygen, allergy to adhesive, severe skin disease that requires treatment)
  • Medical contraindications for VAR (including pregnancy, nursing, severe renal impairment by laboratory test, history of intolerance of varenicline, history of serious suicidal ideation or attempts in the past 5 years)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00756275). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search